T
Tmunity Therapeutics
Unique biotherapeutics company, with application of gene-editing and cell engineering tools in human trial settings,
About Tmunity Therapeutics
Tmunity Therapeutics is a private biotherapeutics company headquartered in Philadelphia, specializing in next-generation T cell immunotherapy. The company focuses on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune diseases. Tmunity leverages broad collaborations with the University of Pennsylvania (UPenn) and the University of Minnesota, utilizing their laboratories and production facilities, alongside its own dedicated resources. The company serves patients suffering from devastating diseases, aiming to save and improve lives through innovative treatments. Tmunity's business model revolves around advancing its proprietary immunotherapies through clinical trials, with the goal of bringing these therapies to market. Revenue is generated through successful clinical trials, partnerships, and potential future commercialization of its therapies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Philadelphia, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 61.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2022 | $0 | — | Kite Pharma | ↗ |
| SERIES BOther financing | Oct 2019 | $75M | $300M | Gilead Sciences · Be The Match BioTherapies · Westlake Village BioPartners · BrightEdge | ↗ |
Growth signals
Latest recorded traffic for Tmunity Therapeutics is 330 monthly website visits, down 41.1% over the last three months. Tmunity Therapeutics's team declined 88.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
- EPEpitherapeutics
Ping An Ventures
Kleiner Perkins
Andreessen Horowitz
Gilead Sciences
Be The Match BioTherapies
Westlake Village BioPartners
BrightEdge
Other known investors2 additional known investors
Kite Pharma
University of Minnesota Twin Cities
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tmunity Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tmunity Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.